Scott ScarneoCSO at Eydisbio Inc.Speaker
Profile
Dr. Scarneo is a formally trained pharmacologist with experience in small molecule immunomodulating therapies. He has published many research articles describing the role of TAK1 in various inflammatory diseases, and his work has advanced the therapeutic understanding of TAK1 and provided critical data to support this target in preclinical studies. Dr. Scarneo currently serves as Director of Research & Development at EydisBio, where he directs in vitro kinase testing of novel analogs, immune cytokine profiling in response to TAK1 inhibition, and coordinates with our CRO collaborators to design and execute preclinical efficacy and safety studies. Dr. Scarneo, has additionally submitted three provisional patents through Duke's Office of Licensing & Ventures describing novel intellectual property surrounding use of TAK1 inhibitors in various disease indications. Dr. Scarneo received his BS in biology and chemistry from Roger Williams University, his MS in Biology from the University of New England, his MBA from Eastern New Mexico University, and his PhD in pharmacology from Duke University School of Medicine.